Tarsus Pharmaceuticals (TARS) Operating Expenses (2019 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Operating Expenses of $168.2 million for Q1 2026, up 60.76% year-over-year from $104.6 million in Q1 2025, and up 5.34% quarter-over-quarter from $159.6 million in Q4 2025.
Tarsus Pharmaceuticals (TARS) Operating Expenses (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Operating Expenses history runs 8 years deep, the most recent figure standing at $168.2 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 60.76% year-over-year to $168.2 million; the TTM figure through Mar 2026 stood at $585.9 million (up 70.89% YoY), while the FY2025 annual figure was $522.3 million, up 72.09% from the prior year.
- Operating Expenses for Q1 2026 stood at $168.2 million, up from $159.6 million in the prior quarter.
- The five-year high for Operating Expenses was $168.2 million in Q1 2026, with the low at $20.1 million in Q1 2022.
- The 5-year median for Operating Expenses is $65.3 million (2024), against an average of $73.1 million.
- The sharpest annual moves came in 2022 and 2024: Operating Expenses slipped 11.7% in 2022, then soared 137.86% in 2024.
- Tarsus Pharmaceuticals' Operating Expenses stood at $25.1 million in 2022, then surged by 129.54% to $57.5 million in 2023, then surged by 57.89% to $90.8 million in 2024, then soared by 75.76% to $159.6 million in 2025, then climbed by 5.34% to $168.2 million in 2026.
- Business Quant data shows TARS's Operating Expenses at $168.2 million in Q1 2026, $159.6 million in Q4 2025, and $133.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Tarsus Pharmaceuticals | 2.99 Bn | 2.54 Bn | 161.80 Mn | 193.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 193.82 Mn |
| Mar 31, 2026 | 168.18 Mn |
| Dec 31, 2025 | 159.64 Mn |
| Sep 30, 2025 | 133.23 Mn |
| Jun 30, 2025 | 124.84 Mn |
| Mar 31, 2025 | 104.62 Mn |
| Dec 31, 2024 | 90.83 Mn |
| Sep 30, 2024 | 73.28 Mn |
| Jun 30, 2024 | 74.12 Mn |
| Mar 31, 2024 | 65.30 Mn |
| Dec 31, 2023 | 57.53 Mn |
| Sep 30, 2023 | 42.81 Mn |
| Jun 30, 2023 | 32.82 Mn |
| Mar 31, 2023 | 27.45 Mn |
| Dec 31, 2022 | 25.06 Mn |
| Sep 30, 2022 | 22.91 Mn |
| Jun 30, 2022 | 20.50 Mn |
| Mar 31, 2022 | 20.06 Mn |
| Dec 31, 2021 | 14.79 Mn |
| Sep 30, 2021 | 16.95 Mn |